Grants and Contributions:
Title:
Cellular Therapy Market Assessment
Agreement Number:
952346
Agreement Value:
$40,000.00
Agreement Date:
Jun 8, 2020 - Dec 31, 2020
Description:
Innovakine has developed an innovative platform technology with the potential to enhance the efficacy and safety of engineered cell therapies across multiple disease indications, including cancer, infectious disease, autoimmunity, transplantation and regenerative medicine. The current project will constitute a competitive landscape analysis that will enable Innovakine to prioritize the most promising medical and commercial applications of its technology.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Vancouver, British Columbia, CA V7X 1L3
Reference Number:
172-2020-2021-Q1-952346
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
776996274
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 109 days. The total amended value is 20,000 dollars.
Amendment Date
Sep 3, 2020
Recipient's Legal Name:
Innovakine Therapeutics Inc.
Federal Riding Name:
Vancouver Centre
Federal Riding Number:
59034
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
3254
Amendments: